List view / Grid view
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
A continuous sorting technique of stem cells on a DLD microfluidic platform may greatly advance cell therapy.
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
Drug Target Review’s Taylor Mixides met with Dr Michelle Sidor, the Director of Neuroscience at Alchemab Therapeutics, and Dr Sifis Pediaditakis at the Society for Neuroscience event this November. This exclusive interview explores neuroscientific research and its pivotal role in steering the company toward future triumphs. Michelle highlights the dynamic…
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline…
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Novel approaches to brain disorder diagnosis and treatment may be developed following a project to form a map of the mouse hippocampus.
Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
17 November 2023 | By
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…
In this article, David Bardsley, Commercial Director, and Nick Foster, Vice President of Discovery CRO at Cresset, explore the challenges that occur when approaching drug discovery in silos and how harnessing advances in technology can help to overcome them.
